Zhaoyong Li

Prof. Zhaoyong Li

Hunan University
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2015 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
Zhaoyong LiZhaoyong Li
Zhaoyong Li
CHChuan Huang
Chuan Huang
CBChun Bao
Chun Bao
LCLiang Chen
Liang Chen
MLMei Lin
Mei Lin
GSGe Shan
Ge Shan

16 September 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
Zhaoyong LiZhaoyong Li
Zhaoyong Li
MHMohammad Q. Hassan
Mohammad Q. Hassan
Stefano VoliniaStefano Volinia
Stefano Volinia
AWAndre J. van Wijnen
Andre J. van Wijnen
JSJanet L. Stein
Janet L. Stein
GSGary S. Stein
Gary S. Stein
Bone morphogenetic proteins (BMPs) are potent morphogens that activate transcriptional programs for lineage determination. How BMP induction of a phenotype is coordinated with microRNAs (miRNAs) that inhibit biological pathways to control cell differentiation, remains unknown. Here, we show by profiling miRNAs during BMP2 induced osteogenesis of C2C12 mesenchymal cells, that 22 of 25 miRNAs which significantly changed in response to BMP2 are down-regulated. These miRNAs are each predicted to target components of multiple osteogenic pathways. We characterize two representative miRNAs and show that miR-133 directly targets Runx2, an early BMP response gene essential for bone formation, and miR-135 targets Smad5, a key transducer of the BMP2 osteogenic signal, controlled through their 3′UTR sequences. Both miRNAs functionally inhibit differentiation of osteoprogenitors by attenuating Runx2 and Smad5 pathways that synergistically contribute to bone formation. Although miR-133 is known to promote MEF-2-dependent myogenesis, we have identified a second complementary function to inhibit Runx2-mediated osteogenesis. Our key finding is that BMP2 controls bone cell determination by inducing miRNAs that target muscle genes but mainly by down-regulating multiple miRNAs that constitute an osteogenic program, thereby releasing from inhibition pathway components required for cell lineage commitment. Thus, our studies establish a mechanism for BMP morphogens to selectively induce a tissue-specific phenotype and suppress alternative lineages.

2 March 2013 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
SWShuyang Wang
Shuyang Wang
JXJianbin Xiang
Jianbin Xiang
Zhaoyong LiZhaoyong Li
Zhaoyong Li
SLShaohua Lu
Shaohua Lu
JHJie Hu
Jie Hu
HZHongguang Zhu
Hongguang Zhu
Colonoscopy remains the standard screening method for detecting colorectal cancer (CRC) at an early stage. However, many people avoid having a colonoscopy because of the fear for its potential complications. Our study aimed to identify plasma microRNAs for preliminarily screening CRC in general population, so that some unnecessary colonoscopies can be avoided. We investigated plasma microRNA expression in three independent cohorts including the discovery (n = 80), training (n = 112), and validation (n = 49) phases recruited at two medical centers. Microarrays were used for screening 723 microRNAs in 80 plasma samples to identify candidate microRNAs. Quantitative reverse‐transcriptase PCR was performed on the 161 training and validation plasma samples to evaluate the candidate microRNAs discovered from microarrays. A logistic regression model was constructed based on the training cohort and then verified by using the validation dataset. Area under the receiver operating characteristic curve (AUC) was used to evaluate the diagnostic accuracy. We identified a panel of miR‐409‐3p, miR‐7, and miR‐93 that yielded high diagnostic accuracy in discriminating CRC from healthy group (AUC: 0.866 and 0.897 for training and validation dataset, respectively). Moreover, the diagnostic performance of the microRNA panel persisted in nonmetastasis CRC stages (Dukes' A‐B, AUC: 0.809 and 0.892 for training and validation dataset, respectively) and in metastasis CRC stages (Dukes' C‐D, AUC: 0.917 and 0.865 for training and validation dataset, respectively). In conclusion, our study reveals a plasma microRNA panel that has potential clinical value in early CRC detection and would play a critical role on preliminarily screening CRC in general population.

Verified
Journal Article
Open access
PDF file
JLJunyun Luo
Junyun Luo
HLHui Liu
Hui Liu
SLSiyu Luan
Siyu Luan
CHChongsheng He
Chongsheng He
Zhaoyong LiZhaoyong Li
Zhaoyong Li
N6-methyladenosine (m6A) is the most prevalent internal modification of eukaryotic messenger RNAs (mRNAs). The m6A modification in RNA can be catalyzed by methyltransferases, or removed by demethylases, which are termed m6A writers and erasers, respectively. Selective recognition and binding by distinct m6A reader proteins lead mRNA to divergent destinies. m6A has been reported to influence almost every stage of mRNA metabolism and to regulate multiple biological processes. Accumulating evidence strongly supports the correlation between aberrant cellular m6A level and cancer. We summarize here that deregulation of m6A modification, resulting from aberrant expression or function of m6A writers, erasers, readers or some other protein factors, is associated with carcinogenesis and cancer progression. Understanding the regulation and functional mechanism of mRNA m6A modification in cancer development may help in developing novel and efficient strategies for the diagnosis, prognosis and treatment of human cancers.

19 October 2018 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
HLHui Liu
Hui Liu
JLJunyun Luo
Junyun Luo
SLSiyu Luan
Siyu Luan
CHChongsheng He
Chongsheng He
Zhaoyong LiZhaoyong Li
Zhaoyong Li

3 July 2019 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
JLJunyun Luo
Junyun Luo
HLHui Liu
Hui Liu
SLSiyu Luan
Siyu Luan
Zhaoyong LiZhaoyong Li
Zhaoyong Li